Top 10 sessions to attend at ASH 2016

November 17, 2016

This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions.

 

This year’s American Society of Hematology (ASH) Conference, held in San Diego, will feature a wide array of sessions. To help you nail down your schedule, Managed Healthcare Executive has identified 10 must-attend sessions.

View our Events Calendar to plan ahead for more upcoming events.

 

 

 

 

This session will focus on how treatment is changing and how it extends beyond conventional chemotherapy. Topics covered include: genomic approaches to optimizing therapy and novel immunotherapeutic approaches.

 

 

 

This session will focus on the heterogeneity of mantle cell lymphoma. Presenters will discuss evaluable biological risk scores with a special focus on minimal residual disease and currently established standards of frontline therapy.

 

 

 

 

This session will focus on challenges and opportunities in the treatment of lymphoma. Presenters will provide an overview of options for patients who fail to respond to R-CHOP induction therapy, an overview of treatment options in this disease, and the availability of checkpoint inhibitors.

 

 

 

This session addresses how to improve the outcome of patients with Hodgkin Lymphoma. Presenters will discuss the major trials testing the role of functional imaging, with FDG positron emission tomography (PET), to direct therapy; data about patients in whom the initial treatment fails; and currently available data about the late toxicity of radiotherapy and chemotherapy.

 

 

 

During this session, presenters will discuss strategies to manage newly diagnosed high-risk patients, what is known about sequencing non-transplant therapies in patients with active disease, and the role of high-dose therapy with stem cell transplant and maintenance therapy in the current era.

 

 

 

During this session, presenters will discuss standard and novel prognostic tools that may aid in the selection of older hematopoietic stem cell transplant (HCT) recipients and inform strategies to reduce transplant morbidity and mortality. They will also discuss data on the KIR gene family as an independent second immunogenetic system, and recent advances in the relationship between the microbiome and important outcomes after allogeneic transplant.

 

 

 

During this session, presenters will provide an overview of recent developments in precision medicine with a focus on the development and interpretation of molecular assays for molecularly targeted therapies.

 

 

 

This session will provide an overview of cancer genetic susceptibility syndromes, with an emphasis on those that predispose to leukemia. Presenters will discuss hereditary predisposition to cancer, discuss genetic susceptibility to myeloid and lymphoid leukemias, and review the clinical challenges and uncertainties associated with genetic testing for heritable predisposition to leukemia.

 

 

 

During the symposium, presenters will discuss the global burden of sickle cell disease. They will also share promising approaches to permanently remedy this genetic disease

 

 

This session will provide attendees with a nice wrap-up overview of the key themes covered at the annual meeting. It will also provide an opportunity to hear about the biggest breakthroughs from the meeting’s abstract presentations.